These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38342128)

  • 21. A clinical evaluation of placental growth factor in routine practice in high-risk women presenting with suspected pre-eclampsia and/or fetal growth restriction.
    Ormesher L; Johnstone ED; Shawkat E; Dempsey A; Chmiel C; Ingram E; Higgins LE; Myers JE
    Pregnancy Hypertens; 2018 Oct; 14():234-239. PubMed ID: 29559205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Planned early delivery versus expectant management to reduce adverse pregnancy outcomes in pre-eclampsia in a low- and middle-income setting: study protocol for a randomised controlled trial (CRADLE-4 Trial).
    Beardmore-Gray A; Vousden N; Charantimath U; Katageri G; Bellad M; Kapembwa K; Chinkoyo S; Vwalika B; Clark M; Hunter R; Seed P; Goudar S; Chappell LC; Shennan A
    Trials; 2020 Nov; 21(1):960. PubMed ID: 33228794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis.
    Duhig KE; Seed PT; Myers JE; Bahl R; Bambridge G; Barnfield S; Ficquet J; Girling JC; Khalil A; Shennan AH; Chappell LC; Hunter RM
    BJOG; 2019 Oct; 126(11):1390-1398. PubMed ID: 31240854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study.
    Gaccioli F; Sovio U; Cook E; Hund M; Charnock-Jones DS; Smith GCS
    Lancet Child Adolesc Health; 2018 Aug; 2(8):569-581. PubMed ID: 30119716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique.
    Manriquez Rocha B; Mbofana F; Loquiha O; Mudenyanga C; Ukah UV; Magee LA; von Dadelszen P
    Pregnancy Hypertens; 2018 Jan; 11():26-31. PubMed ID: 29523269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placental growth factor testing in the management of late preterm preeclampsia without severe features: a multicenter, randomized, controlled trial.
    Peguero A; Herraiz I; Perales A; Melchor JC; Melchor I; Marcos B; Villalain C; Martinez-Portilla R; Mazarico E; Meler E; Hernandez S; Matas I; Del Rio M; Galindo A; Figueras F
    Am J Obstet Gynecol; 2021 Sep; 225(3):308.e1-308.e14. PubMed ID: 33823150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced fetal movement intervention Trial-2 (ReMIT-2): protocol for a pilot randomised controlled trial of standard care informed by the result of a placental growth factor (PlGF) blood test versus standard care alone in women presenting with reduced fetal movement at or after 36
    Armstrong-Buisseret L; Mitchell E; Hepburn T; Duley L; Thornton JG; Roberts TE; Storey C; Smyth R; Heazell AEP
    Trials; 2018 Oct; 19(1):531. PubMed ID: 30285835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Midwifery continuity of care versus standard maternity care for women at increased risk of preterm birth: A hybrid implementation-effectiveness, randomised controlled pilot trial in the UK.
    Fernandez Turienzo C; Bick D; Briley AL; Bollard M; Coxon K; Cross P; Silverio SA; Singh C; Seed PT; Tribe RM; Shennan AH; Sandall J;
    PLoS Med; 2020 Oct; 17(10):e1003350. PubMed ID: 33022010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placental Growth Factor (PlGF) in Women with Suspected Pre-Eclampsia Prior to 35 Weeks' Gestation: A Budget Impact Analysis.
    Duckworth S; Chappell LC; Seed PT; Mackillop L; Shennan AH; Hunter R
    PLoS One; 2016; 11(10):e0164276. PubMed ID: 27741259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy.
    Hofmeyr GJ; Manyame S; Medley N; Williams MJ
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011192. PubMed ID: 31523806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension?
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Ultrasound Obstet Gynecol; 2022 Feb; 59(2):192-201. PubMed ID: 34165863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: The PEACOCK study.
    Duhig KE; Seed PT; Placzek A; Sparkes J; Hendy E; Gill C; Brockbank A; Shennan AH; Thangaratinam S; Chappell LC
    Pregnancy Hypertens; 2021 Jun; 24():90-95. PubMed ID: 33770588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Home telemonitoring versus hospital care in complicated pregnancies in the Netherlands: a randomised, controlled non-inferiority trial (HoTeL).
    Bekker MN; Koster MPH; Keusters WR; Ganzevoort W; de Haan-Jebbink JM; Deurloo KL; Seeber L; van der Ham DP; Zuithoff NPA; Frederix GWJ; van den Heuvel JFM; Franx A
    Lancet Digit Health; 2023 Mar; 5(3):e116-e124. PubMed ID: 36828605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic accuracy of repeat placental growth factor measurements in women with suspected preeclampsia: A case series study.
    Duhig KE; Webster LM; Sharp A; Gill C; Seed PT; Shennan AH; Myers JE; Chappell LC
    Acta Obstet Gynecol Scand; 2020 Aug; 99(8):994-1002. PubMed ID: 32017014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.
    Frampton GK; Jones J; Rose M; Payne L
    Health Technol Assess; 2016 Nov; 20(87):1-160. PubMed ID: 27918253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Da Silva AB; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):400-407. PubMed ID: 32441401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Planned delivery or expectant management for late preterm pre-eclampsia: study protocol for a randomised controlled trial (PHOENIX trial).
    Chappell LC; Green M; Marlow N; Sandall J; Hunter R; Robson S; Bowler U; Chiocchia V; Hardy P; Juszczak E; Linsell L; Placzek A; Brocklehurst P; Shennan A
    Trials; 2019 Jan; 20(1):85. PubMed ID: 30691508
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.